Ultragenyx Pharmaceutical Raises FY24 Revenue Guidance From $500M-$530M To $530M-$550M Vs $513.16M Est.
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical has raised its FY24 revenue guidance from $500M-$530M to $530M-$550M, surpassing the $513.16M estimate. Crysvita revenue is expected to be towards the upper end of $375M-$400M, and Dojolvi revenue is projected to be $75M-$80M. Net cash used in operations is expected to be less than $400M.
August 01, 2024 | 8:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceutical has increased its FY24 revenue guidance to $530M-$550M, exceeding the previous estimate of $513.16M. This positive revision is driven by strong expectations for Crysvita and Dojolvi revenues.
The increase in revenue guidance indicates strong performance and positive future prospects for Ultragenyx. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100